MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype

Lynam‐Lennon, Niamh; Heavey, Susan; Sommerville, Gary; Bibby, Becky A.S.; Ffrench, Brendan; Quinn, Jennifer A.; Gasch, Claudia; O’Leary, John; Gallagher, Michael; Reynolds, John V.; Maher, Stephen G.

doi:10.18632/oncotarget.13940

Cited by 36 publications

(47 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, numerous studies demonstrated that miRNAs serve important roles in various carcinomas (22)(23)(24)(25)(26). In addition, Polioudakis et al (27) reported that miRNAs are located at 50% of all fragile regions or sites presenting copy number alterations in cancer.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑191‑5p exerts a tumor suppressive role in renal cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Renal cell carcinoma (RCC) is a common tumor of the urinary system. Previously, miR-191-5p has been reported to be associated with various types of cancer; however, its specific functions in RCC have not been investigated to date. In the present study, the expression of miR-191-5p in the 786-O and ACHN cell lines was detected in vitro by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The results of RT-qPCR revealed that miR-191-5p was significantly downregulated in the two cell lines compared with the 293T cell line. miR-191-5p was also significantly downregulated in RCC tissue compared with paired normal tissue. In addition, the effects of miR-191-5p on cell proliferation, migration, invasion and apoptosis were examined by CCK-8, MTT, wound scratch, Transwell and flow cytometry assays. Downregulation of miR-191-5p was observed to promote cell proliferation, migration and invasion, as well as to repress the cell apoptosis of 786-O and ACHN cells. Therefore, the current study suggests that miR-191-5p functions as a tumor suppressor in RCC. Further studies are required to uncover the underlying signaling pathway of miR-191-5p and its potential role as a biomarker for early detection and prognosis prediction, and as a therapeutic target of RCC.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑191‑5p exerts a tumor suppressive role in renal cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…miR-17-5p suppresses C6orf120 expression to decrease CSCs chemo-and radioresistance. Therefore, miR-17-5p could be a biomarker for CSC resistance evaluation during EAC treatment [151].…”

Section: Mir-17-5pmentioning

confidence: 99%

microRNA: The Impact on Cancer Stemness and Therapeutic Resistance

Jiao

Qian

et al. 2019

Cells

View full text Add to dashboard Cite

Cancer ranks as the second leading cause of death worldwide, causing a large social and economic burden. However, most anti-cancer treatments face the problems of tumor recurrence and metastasis. Therefore, finding an effective cure for cancer needs to be solved urgently. Recently, the discovery of cancer stem cells (CSCs) provides a new orientation for cancer research and therapy. CSCs share main characteristics with stem cells and are able to generate an entire tumor. Besides, CSCs usually escape from current anti-cancer therapies, which is partly responsible for tumor recurrence and poor prognosis. microRNAs (miRNAs) belong to small noncoding RNA and regulate gene post-transcriptional expression. The dysregulation of miRNAs leads to plenty of diseases, including cancer. The aberrant miRNA expression in CSCs enhances stemness maintenance. In this review, we summarize the role of miRNAs on CSCs in the eight most common cancers, hoping to bridge the research of miRNAs and CSCs with clinical applications. We found that miRNAs can act as tumor promoter or suppressor. The dysregulation of miRNAs enhances cell stemness and contributes to tumor metastasis and therapeutic resistance via the formation of feedback loops and constitutive activation of carcinogenic signaling pathways. More importantly, some miRNAs may be potential targets for diagnosis, prognosis, and cancer treatments.

show abstract

“…Until recently, some progresses were obtained in the eld of neoadjuvant radiotherapy resistance. For example, MiR-17-5p has been reported to signi cantly enhance the sensitivity of X-rays to radioresistant cells as well as downregulate and promote antiradioactive phenotypes in esophageal adenocarcinoma cancer stem-like cells [3]. Overexpression of TCN1 is reportedly associated with adverse treatment responses and outcomes in rectal cancer patients receiving concurrent neoadjuvant chemoradiotherapy, indicating the potential prognostic value of this gene [4].…”

Section: Introductionmentioning

confidence: 99%

Identification of neoadjuvant radiotherapy resistance genes in rectal cancer using integrated bioinformatics analysis

Liao

Zhang²,

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

The incidence of rectal cancer is increasing year by year. And most patients have been diagnosed in the advanced stages largely because of the special anatomical location of the rectum, resulting in uneasy diagnosis in its early stage. The combination of radiotherapy and chemotherapy is widely accepted as effective treatment to the rectal cancer, significantly reduce the local recurrence rate and improve long-term survival, but the occurrence of radiotherapy resistance of rectal cancer strikingly weaken the responding of treatment. So finding reasons or factors leading to the resistance of neoadjuvant radiotherapy for rectal cancer become very urgent not just for the current clinic but also for development of new therapeutical approaches. To identify potential biomarkers associated with neoadjuvant radiotherapy resistance in rectal cancer using bioinformatics analysis. Firstly, we extracted relevant data from GEO database and analyzed the corresponding data by a series of analytic methods. Then, the candidate genes were identified by performing of the analysis of protein-protein interaction network, KEGG and GO, subsequently comfirmed at the levels of mRNA and Protein with Oncomine and The Human Protein Atlas respectively. Furthermore, these comfirmed genes were submitted to CMap analysis to identify candidate therapeutic compounds for neoadjuvant radiotherapy resistance. We found that the abnormal expression of some chemokines were tightly associated with the rectal cancer neoadjuvant radiotherapy resistance. Especially the upreuglation of Chemokines 9(CXCL9) and Chemokines 10(CXCL10) and downregulation of Chemokines 13(CXCL13) and Chemokines 5(CCL5) might be the potential biomarks of the radiotherapy resistance of rectal cancer. Through a series of analyses, the molecules that may be related to the radiotherapy resistance of rectal cancer were identified that may have a hint effect on the treatment of radiotherapy resistance of rectal cancer.

show abstract

MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype

Cited by 36 publications

References 59 publications

MicroRNA‑191‑5p exerts a tumor suppressive role in renal cell carcinoma

MicroRNA‑191‑5p exerts a tumor suppressive role in renal cell carcinoma

microRNA: The Impact on Cancer Stemness and Therapeutic Resistance

Identification of neoadjuvant radiotherapy resistance genes in rectal cancer using integrated bioinformatics analysis

Contact Info

Product

Resources

About